INTRODUCTION
Atherosclerosis is a lifelong, inflammatory arterial disease that starts in childhood. The condition eventually involves all three layers of the arterial wall but is thought to begin in the intima. The first pathological sign is the collection of lipid material in the subintimal space, due to increased endothelial cell permeability. The triggers for altered endothelial function are many and may be genetic or acquired (e.g. family history, smoking, elevated cholesterol). In response to the accumulation of lipid, monocytes and other inflammatory cells migrate from the bloodstream and attempt to ingest and remove the lipid material. This chronic inflammatory response also serves to activate a cytokine cascade, however, resulting in the recruitment of smooth muscle cells into the area and the formation of a necrotic lipid pool (known as the lipid core) and a protective smooth muscle fibrous cap.
A balance is thus struck between the reparative effects of local smooth muscle cell synthetic activity, on the one hand, and the destructive enzymes and cytokines produced by the inflammation at the core of the plaque, on the other hand. If that balance is tipped toward inflammation, there can be breakdown of the fibrous cap of the plaque (plaque rupture). This process allows flowing blood to be exposed to the thrombogenic lipid core and can precipitate acute blockage of the artery by clot. Consequently, myocardial infarction, stroke, and peripheral thrombus embolization may occur. Eventually, often over several decades, the plaque can occupy more and more of the arterial lumen and restrict blood flow during times of increased demand, such as exercise. This gradual process can lead to effort-induced chest tightness, or angina.
Inflammation within atherosclerotic plaques is thus the main force behind plaque rupture and clinical events. 1 The ability to quantify plaque inflammation might allow more-accurate stratification of patient risk, better monitoring of response to therapy, and rapid evaluation of novel therapeutic drugs by serial imaging. Conventional imaging modalities, such as X-ray angiography, provide an excellent appreciation of the artery lumen but cannot provide information about the structure of a plaque or its inflammatory state. The search is on, therefore, for alternative-preferably noninvasive-techniques that can measure inflammation. The small size of most atherosclerotic plaques and their anatomical proximity to other structures place considerable demands on any candidate imaging systems.
In this article, we discuss the advantages and disadvantages of MRI, CT, and nuclear imaging techniques in the imaging of macrophages, the main cell type responsible for plaque inflammation. 2 We have aimed to highlight imaging modalities that are either in current clinical use or close to the point of being so. Other moreexperimental approaches, including invasive intra-arterial imaging, optical imaging (near infrared spectroscopy and optical coherence tomography), thermography, and ultrasound, have been comprehensively reviewed elsewhere. 3,4
IMAGING INFLAMMATION USING MRI
MRI is a noninvasive modality that generates pictures from the analysis of radiowaves emitted from objects placed within the strong magnetic field of the scanner. Variability in the distribution of water allows tissues to be distinguished from one another on high-resolution images. Due to the lack of ionizing radiation, the technique can be used safely in all age groups and repeated scanning is possible.
MRI has excellent spatial resolution, approaching 100 μm, but a low sensitivity, which means that there must be a considerable inherent disparity between two structures before signal differences can be appreciated on an MR image. The sensitivity of MRI can be increased by the use of extraneous contrast agents, such as gadolinium, which alter the relaxivity of the local tissues. MRI has the distinct advantage of relying on radiowaves, rather than ionizing radiation, to generate images. Several aspects of plaque structure, including size, wall thickness, integrity of the fibrous cap, and the presence of inflammation, can be assessed using MRI. 5−8
Ultrasmall super-paramagnetic iron oxide particles as contrast agents A promising approach for imaging macrophages involves the use of a contrast agent that consists of ultrasmall super-paramagnetic particles of iron oxide (USPIO). When administered intravenously to patients with carotid atherosclerosis, the particles are taken up by macrophages, probably via surface scavenger receptors, which generates negative contrast on T2-weighted magnetic resonance images. 9−13 The degree of USPIOinduced signal reduction has been shown to be proportional to the macrophage content of symptomatic carotid plaques, with electron microscopy confirming the intracellular uptake of USPIO into these cells. 10 This technique has also revealed the presence of background inflammatory activity, even within contralateral asymptomatic carotid plaques, 9 which supports the theory of widespread vascular arteritis in symptomatic individuals. 13, 14 Furthermore, a positive correlation has been observed between the degree of inflammation, as detected by USPIO imaging, and the level of biomechanical stress within the plaque (estimated from geometrical strain imaging), which is another risk factor for plaque vulnerability. 9
Super-paramagnetic iron oxide nanoparticles as contrast agents
The use of complementary contrast agents that target two different macrophage ligands frequently found together in high-risk plaques has been reported by Smith et al. 15 The authors used superparamagnetic iron oxide nanoparticles (SPIONs) that were derivatized from annexin A5; their aim was to target atherosclerotic lesions, as annexin A5 recognizes apoptotic cells (by their surface expression of phosphatidylserine). This approach generated images in a rabbit model of atheroma using much lower contrast concentrations than those required using untargeted SPIONs. 15 
Gadolinium-loaded immunomicelles
The macrophage scavenger receptor is responsible for-among other things-ingestion of oxidized LDL within atherosclerotic plaques. These receptors have also been directly targeted for imaging, with the idea that they will only be present within an activated subset of macrophages, and so imaging their density could be advantageous. This approach has been attempted in an animal model of atherosclerosis, using gadolinium-loaded immunomicelles raised against the scavenger receptor. 16 The immunomicelle constructs allow significant amounts of contrast agent to be delivered to the imaging target by offering multiple binding sites for gadolinium per molecule. The authors demonstrated a significantly higher contrast increase (79%) using targeted immunomicelles compared a r t i c l e august 2008 vol 5 supplement 2 rudd and FaYad nature clinical practice cardiovascular medicine S13 www.nature.com/clinicalpractice/cardio with a nontargeted approach (34%) on MRI ( Figure 1 ). Both immunomicellular approaches were much more successful at increasing the contrast than was using gadolinium alone, which failed to enhance the plaques at all.
IMAGING INFLAMMATION USING CT
CT imaging generates data based on the absorption of X-rays by the tissue being imaged. The scans are rapidly acquired and are reproducible, but require ionizing radiation and frequently the use of iodinated contrast agents. The latest generation of multidetector CT scanners have spatial resolution that is not quite as high as that of MRI (approximately 300 μm), but the image data are rapidly acquired in comparison with either MR or nuclear techniques. In addition, the temporal resolution of these scanners, which is essential for imaging the fast moving coronary arteries, is excellent (<100 ms) and provides highly reproducible measurements of vessel stenosis. 17 Using iodinated contrast agents, it is possible to classify plaques on the basis of both their appearance and the Hounsfield unit values of their constituent parts. A novel approach to imaging macrophages by CT involves the use of an iodinated contrast agent (N1177) that has higher specificity for plaque macrophages than do standard clinical contrast agents. 23 This agent was shown to accumulate within cultured macrophages in vitro, probably via scavenger receptors, although this process has not yet been fully established. In a rabbit model, CT imaging of atherosclerotic aortas 2 h after injection of N1177 allowed much better visualization of plaque macrophages than did imaging using standard iodinated contrast agent (Figure 2) , and electron microscopy demonstrated uptake of the agent into macrophages.
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IMAGING INFLAMMATION USING NUCLEAR TECHNIQUES
Nuclear imaging methods (PET and single-photon emission computed tomography [SPECT]) have the highest sensitivity of any imaging modality commonly used for plaque imaging. Rather than relying on the use of an external beam of X-rays, like CT imaging, nuclear techniques involve the administration of intravenous radioisotope to the patient. After allowing the radioisotope to circulate, images are generated by analysis of photons emitted from the patient, reflecting the distribution of the tracer within the body. Both PET and SPECT have low spatial resolution in comparison with MRI and CT, however. Other drawbacks include the use of ionizing radiation and a fairly long acquisition time, to allow circulation and uptake of the administered tracer material into the cellular target. These images were acquired in two separate imaging sessions. Before injection of the contrast agent, the atherosclerotic plaque (arrowheads) could not be differentiated from the surrounding tissues; a strong enhancement of the plaque was detected 2 h after injection of N1177 (but not the conventional contrast agent). Regions of high density in the CT scan acquired 2 h after the injection of N1177 were identified using a color scale and combined with the aortic angiography obtained from the same animal during injection of the contrast agent. In a novel study, [ 18 F]-FDG PET was combined with CT to track the regression of atherosclerotic plaque inflammation in response to statin therapy. 31 The investigators recruited patients who required imaging as part of their cancer management and allocated them to either lowdose statin therapy or placebo treatment for 3 months. A significantly enhanced reduction in plaque inflammation was seen in the patients treated with statin compared with those patients receiving placebo treatment (Figure 3 ).
An important disadvantage of nuclear imaging is the use of radiation. Doses of injected [ 18 F]-FDG could be reduced by using more efficient detector materials with improved photon sensitivity. Furthermore, Bayesian reconstruction approaches might facilitate improved spatial resolution across the entire field of view for the next generation of machines, which would allow the same image quality to be obtained with a lower dose of radiation.
Imaging inflammation using SPECT
Imaging apoptosis
Apoptosis is common in atherosclerotic plaques and is noted frequently in both resident macrophages and vascular smooth muscle cells. This process seems to increase the risks of fibrous cap rupture and of transformation to a vulnerable phenotype. 32 As mentioned, annexin A5 has a high affinity for phosphatidylinositol expressed on the surface of apoptotic cells. Accordingly, technetium-99m-labeled annexin A5 has been used for noninvasive SPECT imaging of experimental atherosclerotic lesions in rabbits, 33 porcine coronary arteries, 34 and apolipoprotein E-deficient mice, 35 as well as in imaging advanced carotid artery disease in patients. 36 A direct correlation between signal intensity and plaque macrophage content has been observed; there was no such relationship between signal intensity and the ncpcm_2007_178f3.eps a r t i c l e number of smooth muscle cells, which indicates a degree of cell specificity. An intervention study has been performed using a combination of withdrawal of highfat diet and treatment with statin to assess any changes in the level of apoptosis in rabbits with experimental atherosclerotic lesions. Clear reductions were noted in the uptake of technetium99m-labeled annexin A5 into the lesions, which paralleled their histological regression. 37 The use of technetium-99m-labeled annexin A5 to assess apoptosis in atherosclerotic plaques might lack some specificity, as annexin A5 also shows a predilection for binding to platelets that express phosphatidylserine within thrombi. 38 This might not be an important issue, however, and might, in fact, be an advantage, because the presence of a clot in association with plaques is likely to point to a complicated, high-risk lesion.
Imaging plaque matrix metalloproteinase activity
Attempts have also been made to image the activity of MMPs within atherosclerotic plaques by labeling an artificial, broad-spectrum inhibitor of this enzyme family. Several MMPs are involved in plaque disruption, and their expression becomes upregulated in the vulnerable plaque phenotype for reasons that are unknown. 39 MMPs can promote plaque destabilization by degrading the extracellular components of the protective fibrous cap that separates the flowing blood from the thrombogenic lipid core of the plaque. Statins exert part of their beneficial effect by reducing the expression and activation of plaque MMPs. 40 Such reduced activity has been imaged in vivo in atheroma-prone experimental mouse models using SPECT 41 and with greater resolution using PET to visualize an [ 18 F]-labeled synthetic MMP inhibitor. 42 
CONCLUSIONS
Atherosclerosis imaging can be performed using several platforms. CT, MRI, and nuclear imaging techniques each offer advantages and disadvantages. The future will presumably see the use of combined, complementary modalities to give different pieces of information in real time about the vascular health of the patient. Prospective clinical studies are still required to prove the value of these techniques in predicting risk of cardiovascular events. Other applications may include using imaging as an early marker of efficacy in drug trials and the combined use of imaging, serum biomarkers, and genetic readouts to stratify individual risk and benefit from therapy. 
